האיחוד האירופי - קרואטית - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimetil fumarat - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

בוסניה והרצגובינה - קרואטית - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

novartis ba d.o.o. - inklisiran - rastvor za injekciju u napunjenoj šprici - 284 mg/1 šprica - 1 napunjena šprica sa 1,5 ml rastvora za injekciju sadrži: 284 mg inklisirana u obliku inklisiran natrija (189 mg/ml)

בוסניה והרצגובינה - קרואטית - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

novartis ba d.o.o. - inklisiran - rastvor za injekciju u napunjenoj šprici - 284 mg/1 šprica - 1 napunjena šprica sa 1,5 ml rastvora za injekciju sadrži: 284 mg inklisirana u obliku inklisiran natrija (189 mg/ml)

האיחוד האירופי - קרואטית - EMA (European Medicines Agency)

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

האיחוד האירופי - קרואטית - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - lijekovi koji se koriste u dijabetesu - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 i 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

בוסניה והרצגובינה - קרואטית - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

viatris bh d.o.o. - fondaparinuks - rastvor za injekciju u napunjenoj šprici - 7,5 mg/0.6 ml - 1 napunjena šprica sadrži 7,5 mg fondaparinuks natrija u 0,6 ml rastvora za injekciju

בוסניה והרצגובינה - קרואטית - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

viatris bh d.o.o. - fondaparinuks - rastvor za injekciju u napunjenoj šprici - 10 mg/0.8 ml - 1 napunjena šprica sadrži 10 mg fondaparinuks natrija u 0,8 ml rastvora za injekciju

האיחוד האירופי - קרואטית - EMA (European Medicines Agency)

fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - svi ostali terapeutski proizvodi - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.

האיחוד האירופי - קרואטית - EMA (European Medicines Agency)

accord healthcare s.l.u. - Толваптан - neprimjereni adh sindrom - diuretici, - tolvaptan is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (siadh).

האיחוד האירופי - קרואטית - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - neoplazme dojki - endokrinska terapija - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.